You are here

Eliminating hepatitis C infection in Australia through pharmacy based treatment scale up

Description 
Hepatitis C affects over 230,000 people in Australia. Currently only 1–2% of people with chronic HCV are treated annually. In 2016, the World Health Organization (WHO) has set targets to reduce new HCV infections by 80%, reduce deaths dues to HCV by 65% and eliminate HCV as a public health problem by 2030. With new, effective non-interferon-based treatments it should be possible for Australia to achieve these elimination targets. Key to our success in reducing HCV-related deaths and new infections in Australia will be the upscaling of treatment for all people with chronic HCV infection, including those currently transmitting HCV who are chiefly people you inject drugs. New community-based treatment programs in pharmacies, primary care, drug and alcohol services and community organisations are being rolled out locally. The project will aim to explore interventions to support pharmacies and pharmacists to 1) improve risk assessment; 2) offer testing and treatment; and 3) expand workforce. The outcomes will help facilitate treatment uptake and improve the quality of care.
Essential criteria: 
Minimum entry requirements can be found here: https://www.monash.edu/admissions/entry-requirements/minimum
Keywords 
hepatitis C, treatment, elimination, pharmacy, pharmacology, microbiology, anatomy, developmental biology, molecular biology, biochemistry, immunology, human pathology, clinical, neuroscience
Available options 
PhD/Doctorate
Masters by research
Honours
BMedSc(Hons)
Time commitment 
Full-time
Part-time
Top-up scholarship funding available 
No
Physical location 
Alfred Research Alliance
Co-supervisors 
Dr 
Alisa Pedrana
Prof 
Margaret Hellard

Want to apply for this project? Submit an Expression of Interest by clicking on Contact the researcher.